NEW YORK (GenomeWeb) – Roka Bioscience has amended a loan and security agreement with Comerica Bank to increase the amount it is borrowing to $10 million from $5 million, the company said in a document filed with the US Securities and Exchange Commission. 

The firm said it used the proceeds from the financing to repay a $5 million loan to TriplePoint Capital dating from November 2013. The loan agreement between the two companies has been terminated. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.